PharmaCyte Biotech (PMCB) announced the successful monetization of its stake in Femasys (FEMY). Following the monetization of the stake, PharmaCyte’s cash and marketable securities are expected to increase to approximately $20M, up from $13.3M as of July 31.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMCB: